Caltech vs. Bio-Rad: ddPCR Patent Infringement Case Dismissed After 120 Days

In a case closely watched by the life sciences and genomics instrumentation community, California Institute of Technology (“Caltech”) filed a patent infringement action against Bio-Rad Laboratories in the Northern District of California, targeting two of Bio-Rad’s flagship droplet digital PCR (ddPCR) product lines. The case—filed February 18, 2025 and closed June 18, 2025—resolved in just 120 days with a dismissal, raising strategic questions about early-stage patent litigation tactics in the high-value diagnostics and genomics instrument market.

The dispute centered on U.S. Patent No. 12,168,797 B2, a recently issued patent covering technologies relevant to droplet-based digital PCR systems. For patent attorneys, IP professionals, and R&D teams operating in the precision medicine and genomics instrumentation space, this case offers instructive signals about assertion strategy, early resolution mechanics, and freedom-to-operate risk in a rapidly evolving technology sector.

Case Overview

The Parties

The Patent at Issue

This case centered on **U.S. Patent No. 12,168,797 B2** (Application No. 18/352,112), a recently issued patent directed to technologies applicable to droplet-based digital PCR (ddPCR) workflows.

• • US 12,168,797 B2 — Technologies applicable to droplet-based digital PCR workflows

Litigation Timeline & Legal Analysis

Litigation Timeline & Procedural History

The case was filed in the U.S. District Court for the Northern District of California, a venue renowned for its patent litigation sophistication and experienced judiciary. The 120-day total duration from filing to dismissal is notably short.

Outcome

The case was **dismissed** approximately four months after filing. No publicly disclosed damages award or injunctive relief order appears in the case record. The dismissal basis was not accompanied by a published merits ruling, indicating the parties likely reached a negotiated resolution—potentially a licensing agreement, covenant not to sue, or settlement—before any substantive judicial determination on infringement or validity.

The specific financial terms, if any, were not disclosed, which is consistent with standard settlement practice in patent cases of this nature.

Verdict Cause Analysis

The case was initiated as a straightforward infringement action. Because the matter resolved before any responsive pleading from Bio-Rad was filed on the merits (the stipulated extension pushed the response to April 14, 2025, and the case closed June 18, 2025), no publicly available claim construction order, invalidity ruling, or infringement finding was issued. The early procedural trajectory—particularly Bio-Rad’s retention of Jones Day and seasoned patent litigator Edward Reines—signals that Bio-Rad was prepared to mount a vigorous defense, which may have influenced the calculus toward early resolution.

Legal Significance

Several legally significant observations emerge from this procedural record:

• Patent Recency: U.S. Patent No. 12,168,797 B2 is a recently issued patent. Asserting newly issued patents can be tactically advantageous, but they may also face expedited IPR challenges.
• Venue Selection: Filing in the Northern District of California—Bio-Rad’s home jurisdiction—suggests Caltech was confident in its position or strategically chose proximity for settlement discussions.
• Early Dismissal Pattern: The 120-day lifecycle without substantive motion practice is consistent with a pre-answer settlement or license negotiation pattern increasingly observed in academic institution patent enforcement actions.